Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF1OUP)

• Drug Name: ACE-1334 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Systemic sclerosis	4A42	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMF1OUP

Molecule-Related Drug Atlas

Drug(s) Targeting Transforming growth factor beta 1 (TGFB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pirfenidone	DM6VZFQ	Idiopathic pulmonary fibrosis	CB03.4	Approved	[3]
A435	DMJCL7X	Aggressive cancer	2A00-2F9Z	IND submitted	[4]
TG-C	DMLCXPD	Arthritis	FA20	Phase 3	[5]
LY2157299	DMP8HW1	Arteriosclerosis	BD40	Phase 2/3	[6]
Disitertide	DM2QBDS	Macular degeneration	9B78.3	Phase 2	[7]
SRK-181	DM0EWMT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
ABBV-151	DMIQXDJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
Mannose phosphate	DM1LM7D	Lesion	8A00-8C12	Discontinued in Phase 2	[10]
ART-144	DMEVT4I	Osteoarthritis	FA00-FA05	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transforming growth factor beta 1 (TGFB1)	TTR9XHZ	TGFB1_HUMAN	Antagonist	[2]

References

• [1] ClinicalTrials.gov (NCT04948554) A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants With Systemic Sclerosis. U.S.National Institutes of Health.
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Clinical pipeline report, company report or official report of Klus Pharma
• [5] Clinical pipeline report, company report or official report of Tissue Gene, Inc.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Perspectives of TGF-beta inhibition in pancreatic and hepatocellular carcinomas. Oncotarget. 2014 January; 5(1): 78-94.
• [8] Clinical pipeline report, company report or official report of Scholar Rock.
• [9] Clinical pipeline report, company report or official report of AbbVie.
• [10] The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-beta1 pathway in human lung fibroblasts. Immunol Lett. 2015 Jun;165(2):90-101.
• [11] Pharmaceutical products of TORREYA partners. December 2011.